Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $522.37, for a total value of $4,962,515.00. Following the transaction, the chief executive officer owned 324,443 shares in the company, valued at $169,479,289.91. This trade represents a 2.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Performance

United Therapeutics stock opened at $517.71 on Friday. The company’s fifty day moving average price is $543.63 and its 200 day moving average price is $532.44. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The stock has a market capitalization of $21.98 billion, a P/E ratio of 19.11, a P/E/G ratio of 1.76 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.63 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 26.65 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Leuthold Group LLC raised its holdings in shares of United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after acquiring an additional 3,126 shares during the period. UBS Group AG grew its holdings in shares of United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after purchasing an additional 70,445 shares during the period. Perpetual Ltd acquired a new stake in United Therapeutics during the fourth quarter worth about $1,059,000. Brookstone Capital Management raised its stake in United Therapeutics by 25.4% during the fourth quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock worth $3,227,000 after purchasing an additional 1,342 shares during the period. Finally, LBP AM SA purchased a new position in United Therapeutics during the fourth quarter worth about $9,745,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on UTHR shares. Morgan Stanley set a $516.00 price objective on United Therapeutics in a report on Thursday, May 7th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $648.33.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.